宝莱特(300246) - 2018 Q1 - 季度财报

Financial Performance - Total operating revenue for Q1 2018 was CNY 185,181,134.67, an increase of 17.74% compared to CNY 157,281,594.04 in the same period last year[7]. - Net profit attributable to shareholders was CNY 18,830,468.14, reflecting a growth of 10.07% from CNY 17,107,414.82 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 17,217,134.42, up by 8.31% from CNY 15,896,811.67 in the previous year[7]. - Basic earnings per share increased to CNY 0.1289, a rise of 10.08% compared to CNY 0.1171 in the same quarter last year[7]. - The company achieved total operating revenue of 185.18 million yuan, an increase of 17.74% compared to the same period last year[20]. - Operating profit for the current period was ¥25,068,503.27, compared to ¥22,199,205.06 in the previous period, reflecting a growth of approximately 8.4%[38]. - Net profit for the current period was ¥21,889,819.85, an increase from ¥20,058,231.60, which is a growth of about 9.1%[38]. - Earnings per share (EPS) for the current period was ¥0.1289, compared to ¥0.1171 in the previous period, showing an increase of approximately 15.4%[39]. - The company reported a total comprehensive income of ¥21,885,929.82, compared to ¥20,058,231.60 in the previous period, reflecting an increase of about 9.1%[39]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 858,077,853.07, marking a 7.23% increase from CNY 800,223,983.68 at the end of the previous year[7]. - The net assets attributable to shareholders were CNY 524,388,181.56, which is a 3.72% increase from CNY 505,558,216.60 at the end of the last year[7]. - Total current assets increased to CNY 489,155,570.30 from CNY 458,572,219.39, representing a growth of approximately 6.3%[29]. - Total non-current assets grew to CNY 368,922,282.77 from CNY 341,651,764.29, indicating an increase of around 8.0%[30]. - Total liabilities increased to CNY 282,110,060.19 from CNY 246,145,507.47, representing a rise of approximately 14.6%[31]. - Total equity attributable to shareholders rose to CNY 524,388,181.56 from CNY 505,558,216.60, reflecting an increase of about 3.5%[32]. Cash Flow - The company reported a net cash flow from operating activities of CNY -8,872,721.88, slightly worsening from CNY -8,743,703.43 in the previous year[7]. - Cash flow from operating activities was ¥184,573,618.50, up from ¥147,743,539.80, indicating a growth of about 25%[44]. - The total cash inflow from operating activities was 189,021,173.41 CNY, compared to 151,753,160.95 CNY in the previous period, marking an increase of about 24.5%[45]. - The total cash outflow from operating activities was 197,893,895.29 CNY, up from 160,496,864.38 CNY in the previous period, indicating an increase of approximately 23.3%[45]. - The ending balance of cash and cash equivalents was 147,407,329.02 CNY, down from 178,961,488.25 CNY in the previous period, representing a decrease of approximately 17.6%[46]. Operational Strategies - The company has completed the layout of the entire blood dialysis industry chain to mitigate market competition risks[9]. - The company is focusing on group management and internal control to address management risks associated with its expanding scale[10]. - The company is implementing various sales models to reduce collection risks in overseas markets, including payment upon delivery and export credit insurance[10]. - The company plans to enhance marketing efforts and expand its market presence to drive growth in the health monitoring and nephrology medical segments[20]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[38]. Expenses and Financial Changes - Management expenses increased by 4,823,543.15 yuan, a growth of 34.17%, due to the consolidation of newly acquired subsidiaries[18]. - Financial expenses surged by 1,113,618.09 yuan, a dramatic increase of 1093.56%, driven by higher bank loan interest and foreign exchange losses[18]. - The company received government subsidies related to daily operations amounting to 2,901,990.64 yuan, reflecting a 100% increase due to new accounting standards[18]. - Cash and cash equivalents decreased by 2,256,545.38 yuan, a decline of 95.66%, primarily due to bank borrowings by subsidiaries[19].